fda glp-1 compounding warning october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our fda glp-1 compounding warning october

1 ADHD

AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication

Our providers draw on the available research and clinical experience to design thoughtful protocols while being transparent about the uncertainty that remains

PRP has been used safely for years in other fields of medicine, like orthopedics, and has a strong track record

They are characterized by an increase in volume (hypertrophy) and in the number of the adipocytes (hyperplasia), without histological stromal-parenchymal changes of the cellular structure and without modifications of the hypodermal and dermal microcirculation